Ticker Details
Agios Pharmaceuticals, Inc. Agios Pharmaceuticals Inc is a biopharmaceutical company which focuses on developing treatments geared towards cancer and rare genetic disorders of metabolism. It also emphasizes on developing potentially transformative small-molecule medicines.
IPO Date:	July 24, 2013
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.67B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.19 | 2.51%
Avg Daily Range (30 D):	$0.49 | 1.73%
Avg Daily Range (90 D):	$0.50 | 1.74%

Institutional Daily Volume
Avg Daily Volume:	.55M
Avg Daily Volume (30 D):	.91M
Avg Daily Volume (90 D):	.79M

Trade Size
Avg Trade Size (Sh.):	73
Avg Trade Size (Sh.) (30 D):	55
Avg Trade Size (Sh.) (90 D):	54

Institutional Trades
Total Institutional Trades:	6,304
Avg Institutional Trade:	$2.36M
Avg Institutional Trade (30 D):	$2.59M
Avg Institutional Trade (90 D):	$2.91M
Avg Institutional Trade Volume:	.06M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$3.28M
Avg Closing Trade (30 D):	$4.52M
Avg Closing Trade (90 D):	$4.55M
Avg Closing Volume:	81.97K

News

Apr 29, 2026 @ 10:27 PM Why Agios Pharmaceuticals Stock Zoomed to a 13% Ga... Source: Eric Volkman

Apr 20, 2026 @ 4:19 PM Here's Why Agios Pharmaceuticals Crashed 23% Today... Source: Lee Samaha

Apr 13, 2026 @ 8:47 AM Alpha Thalassemia (US, EU4, UK, and Japan) Market ... Source: Researchandmarkets.Com

Apr 6, 2026 @ 11:00 AM Agios to Host First Quarter 2026 Financial Results... Source: Na

Mar 31, 2026 @ 4:08 PM Why Agios Pharmaceuticals Stock Is Up More Than 21... Source: James Brumley

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-7.25	$-1.69	$-1.85
Diluted EPS	$-7.25	$-1.69	$-1.85
Revenue	$66.05M	$20.75M	$19.97M
Gross Profit	$59.47M	$19.43M	$18.09M
Net Income / Loss	$-422.6M	$-99.11M	$-108.04M
Operating Income / Loss	$-475.53M	$-110.03M	$-121.58M
Cost of Revenue	$6.58M	$1.32M	$1.88M
Net Cash Flow	$34.64M	$24.47M	$-3.58M
PE Ratio